Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT03739554 is registered in ClinicalTrials.gov with Cyclacel Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03739554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03739554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 25, 2019
Completion date
April 27, 2023
Enrollment
5 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory chronic lymphocytic leukemia